GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cybin Inc (AMEX:CYBN) » Definitions » Minority Interest

Cybin (CYBN) Minority Interest : $0.00 Mil (As of Sep. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Cybin Minority Interest?

Minority interest is the carrying amount of the equity interests owned by non-controlling shareholders, partners, or other equity holders in one or more of the entities included in the reporting entity's consolidated financial statements.

Cybin's minority interest for the quarter that ended in Sep. 2024 was $0.00 Mil.


Cybin Minority Interest Historical Data

The historical data trend for Cybin's Minority Interest can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cybin Minority Interest Chart

Cybin Annual Data
Trend Mar20 Mar21 Mar22 Mar23 Mar24
Minority Interest
- - - - -

Cybin Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Minority Interest Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Cybin Minority Interest Calculation

Minority interest is the carrying amount of the equity interests owned by non-controlling shareholders, partners, or other equity holders in one or more of the entities included in the reporting entity's consolidated financial statements.


Cybin Business Description

Traded in Other Exchanges
Address
100 King Street West, Suite 5600, Toronto, ON, CAN, M5X 1C9
Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The company is focused on advancing psychedelic-based therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions.